META Meta Platforms Inc.

$751.67

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Meta Platforms is poised to leverage its robust AI investments as it approaches its Q3 2025 earnings release, with analysts closely watching how these strategic moves translate into financial performance. Following a remarkable Q2 where Meta's revenue soared to $47.52 billion, surpassing expectations and driving a 10% stock surge, the company now faces the challenge of maintaining momentum amidst recent stock pullbacks. The market anticipates continued growth, with revenue estimates for Q3 set at $49.36 billion, supported by Meta's AI-driven advertising enhancements. The EPS estimate stands at $6.68, yet the whisper number of $7.63 suggests that investors are hopeful for another earnings beat. Despite recent layoffs in its AI division, Meta's strategic focus on AI monetization remains a key driver for future growth. With a market cap of over $1.8 trillion, Meta's ability to meet or exceed these expectations could further solidify its leadership in the digital advertising space and reassure investors of its long-term growth trajectory.

Updated On 10/30/2025

About Meta Platforms Inc.

Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.

Website: https://investor.atmeta.com

Sector
TECHNOLOGY
Industry
SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC.
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1326801
Address
1601 WILLOW ROAD, MENLO PARK, CA, US
Valuation
Market Cap
$1.27T
P/E Ratio
21.01
PEG Ratio
1.00
Price to Book
6.96
Performance
EPS
$23.87
Dividend Yield
0.42%
Profit Margin
37.90%
ROE
37.10%
Technicals
50D MA
$618.72
200D MA
$578.34
52W High
$740.25
52W Low
$412.99
Fundamentals
Shares Outstanding
2B
Target Price
$727.04
Beta
1.28

META EPS Estimates vs Actual

Estimated
Actual

META News & Sentiment

Oct 30, 2025 • Benzinga NEUTRAL
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare - Molina Healthcare ( NYSE:MOH )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Molina To Contact Him Directly To Discuss Their Options
Oct 30, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Notice of completion of the transaction regarding the sale of Northern Horizon Capital AS shares
Northern Horizon Capital AS, the management company of Baltic Horizon Fund, hereby notifies that on 30 October 2025, the previous sole shareholder Northern Horizon A/S ( registered in Denmark under register number 27599397 ) transferred the ownership of this Estonian licensed fund management ...
Oct 30, 2025 • Benzinga NEUTRAL
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of WPP - WPP ( NYSE:WPP )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options
Oct 30, 2025 • Benzinga SOMEWHAT-BULLISH
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex Group - Marex Group ( NASDAQ:MRX )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered In Marex To Contact Him Directly To Discuss Their Options
Oct 30, 2025 • Benzinga NEUTRAL
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - Jasper Therapeutics ( NASDAQ:JSPR )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
Oct 30, 2025 • Benzinga NEUTRAL
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Cytokinetics ( NASDAQ:CYTK )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Sentiment Snapshot

Average Sentiment Score:

0.164
50 articles with scored sentiment

Overall Sentiment:

Bullish

META Reported Earnings

Jul 30, 2025
Jun 30, 2025 (Post market)
1.24 Surprise
  • Reported EPS: $7.14
  • Estimate: $5.90
  • Whisper:
  • Surprise %: 21.0%
Apr 30, 2025
Mar 31, 2025 (Post market)
1.21 Surprise
  • Reported EPS: $6.43
  • Estimate: $5.22
  • Whisper:
  • Surprise %: 23.2%
Jan 29, 2025
Dec 31, 2024 (Post market)
1.34 Surprise
  • Reported EPS: $8.02
  • Estimate: $6.68
  • Whisper:
  • Surprise %: 20.1%
Oct 30, 2024
Sep 30, 2024 (Post market)
0.74 Surprise
  • Reported EPS: $6.03
  • Estimate: $5.29
  • Whisper:
  • Surprise %: 14.0%
Jul 31, 2024
Jun 30, 2024 (Post market)
0.4 Surprise
  • Reported EPS: $5.16
  • Estimate: $4.76
  • Whisper:
  • Surprise %: 8.4%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.39 Surprise
  • Reported EPS: $4.71
  • Estimate: $4.32
  • Whisper:
  • Surprise %: 9.0%
Feb 01, 2024
Dec 31, 2023 (Post market)
0.37 Surprise
  • Reported EPS: $5.33
  • Estimate: $4.96
  • Whisper:
  • Surprise %: 7.5%
Oct 25, 2023
Sep 30, 2023 (Post market)
0.76 Surprise
  • Reported EPS: $4.39
  • Estimate: $3.63
  • Whisper:
  • Surprise %: 20.9%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.07 Surprise
  • Reported EPS: $2.98
  • Estimate: $2.91
  • Whisper:
  • Surprise %: 2.4%

Financials